KD Logo

Analysts review Bristol-Myers Squibb Co.’s rating

Bristol-Myers Squibb Co.’s recently made public that its Chief Executive Officer BOERNER CHRISTOPHER S. acquired Company’s shares for reported $99560.0 on Dec 05 ’23. In the deal valued at $49.78 per share,2,000 shares were bought. As a result of this transaction, BOERNER CHRISTOPHER S. now holds 82,672 shares worth roughly $4.36 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, BOERNER CHRISTOPHER S. bought 3,071 shares, generating $150,049 in total proceeds. Upon buying the shares at $48.86, the Chief Executive Officer now owns 79,384 shares.

Before that, Samuels Theodore R. II bought 8,500 shares. Bristol-Myers Squibb Co. shares valued at $423,385 were divested by the Director at a price of $49.81 per share. As a result of the transaction, Samuels Theodore R. II now holds 35,500 shares, worth roughly $1.87 million.

Bernstein initiated its Bristol-Myers Squibb Co. [BMY] rating to a Mkt perform in a research note published on October 17, 2024; the price target was $56. A number of analysts have revised their coverage, including Barclays’s analysts, who decreased its forecast for the stock in late July from “an Overweight” to “an Equal weight”. Societe Generale also remained covering BMY and has decreased its forecast on March 11, 2024 with a “Hold” recommendation from previously “Buy” rating. Redburn Atlantic revised its rating on February 06, 2024. It rated BMY as “a Neutral” which previously was an “a Buy”.

Price Performance Review of BMY

On Tuesday, Bristol-Myers Squibb Co. [NYSE:BMY] saw its stock jump 1.23% to $52.76. Bristol-Myers Squibb Co. shares have risen nearly 2.83% since the year began. Nevertheless, the stocks have fallen -6.55% over the past one year. While a 52-week high of $56.77 was reached on 03/13/24, a 52-week low of $39.35 was recorded on 07/05/24. SMA at 50 days reached $50.51, while 200 days put it at $47.84.

Levels Of Support And Resistance For BMY Stock

The 24-hour chart illustrates a support level at 52.17, which if violated will result in even more drops to 51.59. On the upside, there is a resistance level at 53.20. A further resistance level may holdings at 53.65. The Relative Strength Index (RSI) on the 14-day chart is 56.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.27, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.38%. Stochastics %K at 43.61% indicates the stock is a holding.

How much short interest is there in Bristol-Myers Squibb Co.?

A steep rise in short interest was recorded in Bristol-Myers Squibb Co. stocks on 2024-09-30, dropping by -2.22 million shares to a total of 20.03 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 22.26 million shares. There was a decline of -11.1%, which implies that there is a negative sentiment for the stock.

Most Popular